Alexion Pharmaceuticals Inc's Suppliers recorded an increase in sales by 22.51 % year on year in Q1 2021, sequentially sales grew by 3.8 %, Alexion Pharmaceuticals Inc recorded an increase in cost of sales by 12.26 % year on year, relative to one quarter ago cost of sales fell by -17.61 % in Q1.
Alexion Pharmaceuticals Inc's Suppliers recorded an increase in sales by 22.51 % year on year in Q1 2021, sequentially sales grew by 3.8 %, Alexion Pharmaceuticals Inc recorded increase in cost of sales by 12.26 % year on year, compare to one quarter ago cost of sales fell by -17.61 % in Q1.
Alexion Pharmaceuticals Inc's Comment on Supply Chain
We currently rely on two manufacturing facilities, Alexions Rhode Island manufacturing
facility (ARIMF) and Lonza Group AG and its affiliates (Lonza), to produce commercial
and clinical bulk quantities of Soliris, and we rely on Lonza for clinical quantities
of asfotase alfa. We produce our clinical and preclinical quantities of our
other product candidates at ARIMF. We also depend on a limited number of third
party providers for other services with respect to our clinical and commercial
requirements, including product finishing, packaging, vialing and labeling.
We have various agreements with Lonza, with remaining total commitments of
approximately $169,000 through 2018. Such commitments may be canceled only in
limited circumstances. If we terminate certain supply agreements with Lonza
without cause, we will be required to pay for product scheduled for manufacture
under our arrangement. Under an existing arrangement with Lonza, we also pay
Lonza a royalty on sales of Soliris manufactured at ARIMF.
Alexion Pharmaceuticals Inc's Comment on Supply Chain
We currently rely on two manufacturing facilities, Alexions Rhode Island manufacturing
facility (ARIMF) and Lonza Group AG and its affiliates (Lonza), to produce commercial
and clinical bulk quantities of Soliris, and we rely on Lonza for clinical quantities
of asfotase alfa. We produce our clinical and preclinical quantities of our
other product candidates at ARIMF. We also depend on a limited number of third
party providers for other services with respect to our clinical and commercial
requirements, including product finishing, packaging, vialing and labeling.
We have various agreements with Lonza, with remaining total commitments of
approximately $169,000 through 2018. Such commitments may be canceled only in
limited circumstances. If we terminate certain supply agreements with Lonza
without cause, we will be required to pay for product scheduled for manufacture
under our arrangement. Under an existing arrangement with Lonza, we also pay
Lonza a royalty on sales of Soliris manufactured at ARIMF.
ALXN's Suppliers Net Income grew by
ALXN's Suppliers Net margin grew in Q1 to
109.82 %
13.45 %
ALXN's Suppliers Net Income grew by 109.82 %
ALXN's Suppliers Net margin grew in Q1 to 13.45 %
Alexion Pharmaceuticals Inc's Suppliers Sales Growth
in Q1 2021 by Industry
Sources:
Alexion Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Alexion Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
11.63 % 